March 3, 2017 / 7:36 AM / 7 months ago

BRIEF-AstraZeneca ties up with Sanofi on respiratory drug

March 3 (Reuters) - Astrazeneca Plc

* Alliance with sanofi pasteur for medi8897

* Medi8897 is a monoclonal antibody (mab) for prevention of lower respiratory tract illness (lrti) caused by respiratory syncytial virus

* Sanofi pasteur will make an upfront payment of eur 120 million and pay up to eur 495 million upon achievement of certain development and sales-related milestones

* Two companies will share all costs and profits equally Source text for Eikon: Further company coverage: (Reporting By London Bureau)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below